Placenta-Powered stem cells aim to treat bone marrow failure
NCT ID NCT06465160
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new cell therapy called MNV-201 for people with low-risk myelodysplastic syndrome (MDS), a bone marrow disorder that causes low blood counts. The treatment uses the patient's own blood stem cells, which are mixed with mitochondria from donated placentas to boost their energy, then infused back. The study will enroll 15 adults who need regular blood transfusions to see if the therapy is safe and can improve anemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MNV-201 (patient's own blood stem cells enriched with mitochondria from donated placenta)
- What this could lead to
- If it works, this could lead to a new way to treat low-risk MDS by improving blood cell production and reducing the need for blood transfusions.
- What could go wrong
- This is a very early (Phase 1) and small (15 people) trial focused on safety. It may not improve anemia or reduce transfusions, and there could be side effects from the cell infusion or the mobilization procedure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shaare Zedek Medical Center
RECRUITINGJerusalem, Israel, 9103102, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?
- Can a new drug offer hope for blood cancers when chemo fails?
- Can a Gene-Targeted pill turn the tide against a rare blood cancer?